- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00542217
Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection
October 10, 2007 updated by: HiberCell, Inc.
Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects
The purpose of this trial is to the assess the safety, pharmacodynamics, and pharmacokinetics of escalating doses of Imprime PGG™ Injection in healthy volunteers.
Study Overview
Detailed Description
The primary objective of this study is to evaluate the safety and tolerability of a single intravenous dose of Imprime PGG versus placebo when administered to healthy adult subjects by assessing the frequency, type, and severity of treatment emergent adverse events.
The secondary objectives are:
- to determine the pharmacodynamics of a single intravenous dose of Imprime PGG when administered to healthy adult subjects by assessing the number of subjects who experience a 15% or more increase from baseline in the percentage of neutrophils with primed CR3; and
- to derive the pharmacokinetic profile of a single intravenous dose of Imprime PGG when administered to healthy adult subjects by assessing the plasma concentration of Imprime PGG versus time.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be aged 18 to 45 years, inclusive
- Have a body weight of 45 to 125 kg, inclusive, and a body mass index less than or equal to 30 kg/m2
- If female, be nonpregnant and nonnursing, and if premenopausal, have a negative urine pregnancy test confirmed prior to enrollment and practicing at least two methods of birth control
- Be healthy as determined by the investigator on the basis of medical history, the physical examination, electrocardiogram, and clinical laboratory test results
- Have the ability to understand the requirements of the study, have provided written informed consent, and agree to abide by the study restrictions and to return for the required assessments
- Have provided written authorization for use and disclosure of protected health information
Exclusion Criteria:
- Have a known hypersensitivity to baker's yeast
- Have a history of tobacco use within 3 months of the Screening Period
- Be a known or suspected abuser of alcohol or other drugs of abuse
- Have an active yeast infection
- Have a positive hepatitis B, hepatitis C, or human immunodeficiency virus test during the Screening Period
- Except as otherwise indicated, have taken any prescription medication within 14 days of study drug administration on Day 0 or over-the-counter medication, herbal preparation, or vitamins within 1 week of study drug administration on Day 0 (The following medications are exempted from this criterion: acetaminophen [maximum 3 g/day], female hormone replacement therapy, and oral contraceptives.)
- Have participated in an investigational drug study within 30 days or five half-lives (whichever is longer) of the Screening Period
- Have donated or lost more than a unit of blood within 30 days of the Screening Period
- Have any clinical condition that, in the opinion of the principal investigator, warrants exclusion from the study for either a scientific, procedural, or safety perspective
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cohort 1
Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
|
|
Placebo Comparator: Cohort 2
Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
|
|
Placebo Comparator: Cohort 3
Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
|
|
Placebo Comparator: Cohort 4
Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
|
|
Placebo Comparator: Cohort 5
Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety and tolerability of a single intravenous dose of Imprime PGG™ Injection (Imprime PGG) versus placebo when administered to healthy adult subjects by assessing the frequency, type, and severity of adverse events.
Time Frame: Prospective
|
Prospective
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
-To determine the pharmacodynamics of a single intravenous dose of Imprime PGG by assessing the number of subjects who experience a 15% or more increase from baseline in the percentage of neutrophils with primed complement receptor 3 (CR3)
Time Frame: Prospective
|
Prospective
|
To derive the pharmacokinetic profile of a single intravenous dose of Imprime PGG, when administered to healthy adult subjects, by assessing the plasma concentration of Imprime PGG versus time.
Time Frame: Prospective
|
Prospective
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Study Completion (Actual)
April 1, 2006
Study Registration Dates
First Submitted
October 10, 2007
First Submitted That Met QC Criteria
October 10, 2007
First Posted (Estimate)
October 11, 2007
Study Record Updates
Last Update Posted (Estimate)
October 11, 2007
Last Update Submitted That Met QC Criteria
October 10, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BIOBG-CL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Imprime PGG
-
HiberCell, Inc.Completed
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
HiberCell, Inc.Merck Sharp & Dohme LLCTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
HiberCell, Inc.Celldex TherapeuticsTerminatedMetastatic Pancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.Merck Sharp & Dohme LLCCompletedAdvanced Melanoma | Triple-Negative Breast CancerUnited States
-
HiberCell, Inc.CompletedColorectal CancerUnited States
-
Lawrence Feldman, MDMerck Sharp & Dohme LLC; HiberCell, Inc.Active, not recruitingNon-Small Cell Lung CancerUnited States
-
HiberCell, Inc.Merck Sharp & Dohme LLCCompletedMalignant Neoplasm of BreastUnited States
-
HiberCell, Inc.WithdrawnPathologic Stage III Cutaneous Melanoma AJCC v8United States